Open AccessTotal Ankle Replacement in Hemophilia
Author(s) -
E. Carlos Rodríguez-Merchán
Publication year - 2020
Publication title -
cardiovasular and hematological disorders. drug targets
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.365
H-Index - 40
eISSN - 2212-4063
pISSN - 1871-529X
DOI - 10.2174/1871529x19666191210110626
Subject(s) - medicine , ankle , ankle replacement , arthropathy , tar (computing) , adverse effect , medline , cochrane library , surgery , physical therapy , osteoarthritis , alternative medicine , pathology , randomized controlled trial , computer science , law , political science , programming language
Severe ankle hemophilic arthropathy can be a calamitous sign of severehemophilia with important inferences for activities of daily living. Aims: To summarize the contemporary, accessible information on Total Ankle Replacement (TAR)for ankle hemophilic arthropathy. Methods: A search of Cochrane Library and PubMed (MEDLINE) regarding the role of TAR inankle hemophilic arthropathy. Results: The insufficient information regarding the results of TAR for hemophilic arthropathy isconfined to scanty case series and case reports. An evaluation of the accessible literature revealsencouraging but inconstant outcomes. The reported rate of adverse events is 33%. The reportedanticipated survival of TAR is 94% at 5 years, 85% at 10 years and 70% at 15 years. Conclusion: Whereas people with advanced hemophilic arthropathy of the ankle are prone to amelioratepain and range of motion following TAR, there is deficient knowledge to regularly recommendits use. Adverse events and infection percentages are disturbing. Moreover, the lack of survivalanalysis knowledge makes it difficult to assess the benefit to people with hemophilia. TAR is ademanding surgical procedure and its survival is not comparable to that after hip or knee replacement.